Works matching AU Jones, Suzanne

Results: 93
    1
    2
    3
    4

    Abstracts and Keywords.

    Published in:
    1999
    By:
    • Potter, Rachel;
    • Goody, Alex;
    • Rees-Jones, Deryn;
    • Jones, Alison;
    • Bown, Nicola;
    • Jones, Suzanne W.
    Publication type:
    Abstract
    5
    6

    Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum].

    Published in:
    International Journal of Nanomedicine, 2019, v. 14, p. 5751, doi. 10.2147/IJN.S207276
    By:
    • Wu, Huali;
    • Infante, Jeffrey R;
    • Keedy, Vicki L;
    • Jones, Suzanne F;
    • Chan, Emily;
    • Bendell, Johanna C;
    • Lee, Wooin;
    • Kirschbrown, Whitney P;
    • Zamboni, Beth A;
    • Ikeda, Satoshi;
    • Kodaira, Hiroshi;
    • Rothenberg, Mace L;
    • III, Howard A Burris;
    • Zamboni, William C
    Publication type:
    Article
    7

    Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.

    Published in:
    International Journal of Nanomedicine, 2015, v. 10, p. 1201, doi. 10.2147/IJN.S62911
    By:
    • Huali Wu;
    • Infante, Jeffrey R.;
    • Keedy, Vicki L.;
    • Jones, Suzanne F.;
    • chan, Emily;
    • Bendell, Johanna C.;
    • lee, Wooin;
    • Kirschbrown, Whitney P.;
    • Zamboni, Beth A.;
    • Ikeda, Satoshi;
    • Kodaira, Hiroshi;
    • Rothenberg, Mace L.;
    • Burris III, Howard A.;
    • Zamboni, William C.
    Publication type:
    Article
    8

    Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors: Adavosertib Plus Durvalumab for Solid Tumors: A Phase I Study: M.R. Patel et al.

    Published in:
    Targeted Oncology, 2025, v. 20, n. 1, p. 127, doi. 10.1007/s11523-024-01110-8
    By:
    • Patel, Manish R.;
    • Falchook, Gerald S.;
    • Wang, Judy S.;
    • Imedio, Esteban Rodrigo;
    • Kumar, Sanjeev;
    • Miah, Kowser;
    • Mugundu, Ganesh M.;
    • Jones, Suzanne F.;
    • Spigel, David R.;
    • Hamilton, Erika P.
    Publication type:
    Article
    9
    10

    A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.

    Published in:
    Targeted Oncology, 2023, v. 18, n. 4, p. 517, doi. 10.1007/s11523-023-00965-7
    By:
    • Bauer, Todd M.;
    • Moore, Kathleen N.;
    • Rader, Janet S.;
    • Simpkins, Fiona;
    • Mita, Alain C.;
    • Beck, J. Thaddeus;
    • Hart, Lowell;
    • Chu, Quincy;
    • Oza, Amit;
    • Tinker, Anna V.;
    • Imedio, Esteban Rodrigo;
    • Kumar, Sanjeev;
    • Mugundu, Ganesh;
    • Jenkins, Suzanne;
    • Chmielecki, Juliann;
    • Jones, Suzanne;
    • Spigel, David;
    • Fu, Siqing
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20

    A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.

    Published in:
    2015
    By:
    • Bendell, Johanna C.;
    • Kelley, Robin K.;
    • Shih, Kent C.;
    • Grabowsky, Jennifer A.;
    • Bergsland, Emily;
    • Jones, Suzanne;
    • Martin, Thomas;
    • Infante, Jeffrey R.;
    • Mischel, Paul S.;
    • Matsutani, Tomoo;
    • Xu, Shuichan;
    • Wong, Lilly;
    • Liu, Yong;
    • Wu, Xiaoling;
    • Mortensen, Deborah S.;
    • Chopra, Rajesh;
    • Hege, Kristen;
    • Munster, Pamela N.
    Publication type:
    journal article
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50